Michael Levitz is a strategic, execution-driven Chief Financial Officer with more than 20 years of public- company medical device experience, including over a decade as CFO leading global, high-growth organizations. Recognized for driving enterprise value, operational excellence, and investor confidence at companies such as Insulet Corporation in diabetes care, Michael combines financial acumen with strategic vision. As a trusted advisor and values-based leader, Michael brings deep experience in finance, corporate governance and organizational performance, along with a passion for advancing medical innovation and empowering high-impact teams. In addition to serving on the board and as chairman of the audit committee of Kandu Inc., Michael is president of PTP Advisory LLC and serves on the advisory board of Thirdwayv Inc. Michael began his career in the high-technology audit practice of Arthur Andersen, is a certified public accountant, and has a degree in business economics with emphasis in accounting from the University of California at Santa Barbara.
Team Group: Board of Directors New
Bret Christinsen
Bret Christensen is a seasoned leader recognized for his exceptional ability to launch innovative solutions, penetrate markets and effectively scale businesses. With over two decades of experience in the healthcare sector, a specialized focus on women’s health and a comprehensive understanding of the broader healthcare landscape, Bret has consistently proven his ability to elevate emerging solutions into market share leaders, solidifying his reputation as a catalyst for growth and success.
Over the course of his distinguished career, Bret has held strategic commercial and general management leadership roles at Hologic (NASDAQ: HOLX), Myriad Genetics (NASDAQ: MYGN) and Insulet (NASDAQ: PODD), where he played a central role in revolutionizing treatments in women’s health care, oncology and diabetes, respectively. His strategic leadership drove significant revenue growth, achieved product commercialization success and advanced groundbreaking therapies that have redefined standards of care.
Bret’s expertise spans diagnostics, therapeutics and medical devices, positioning him as the ideal leader to accelerate Biote to its next level of growth. With a rare blend of business acumen and deep industry insight, he is uniquely equipped to drive Biote’s continued success as a leading educator in hormone optimization and therapeutic wellness while expanding its market presence and reach.
Bret holds a Bachelor of Science from Utah Valley University, a Masters of Business Administration from the University of Utah, David Eccles School of Business and several executive certifications from the University of Chicago Booth School of Business.
William Tai
William Tai is a successful entrepreneur and investor with over 30 years of experience in the technology industry. He is the Founder and Managing Partner of Amed Ventures, a San Francisco Bay Area-based venture capital fund focused on Medical Device and Medical Technologies investments. He is also the former VP of Business Development at CTBC Bank Corp. William has earned a Bachelor’s Degree in Finance from National Chengchi University and an MBA from Baruch College.
Kevin Reilly
Kevin Reilly joined Ally Bridge Group in 2021 and is a Managing Director, Head of Medtech, for the private equity strategy, focused on transactions across healthcare subsectors. Before joining Ally Bridge Group, Kevin was a Principal at CRG, a healthcare investment management firm providing growth capital to companies through the form of long-term debt and equity. Kevin began his career in the Healthcare Investment Banking Group at Stifel. Kevin holds a B.S. in Finance and Information Systems from the University of Maryland.
Leo Petrossian
Dr. Leo Petrossian is the Chief Executive Officer of Kandu Inc., a neurotechnology company formed from the merger of Neurolutions and Kandu Health. He is a seasoned healthcare executive and entrepreneur with deep expertise in bringing transformative medical devices from early development to commercialization. Under his leadership, Neurolutions pioneered the IpsiHand®, the first FDA-cleared brain–computer interface for stroke rehabilitation. Dr. Petrossian is passionate about advancing technologies that expand access, improve outcomes, and reshape standards of care in neurology and beyond.
Dr. Petrossian earned his MBA from the UCLA Anderson School of Management in 2014 and earned his Ph.D. & MS in Biomolecular Nanotechnology & Solid-State Device Physics as an NSF IGERT fellow at Arizona State University in 2007. He also holds a double B.S. in Electrical Engineering & Biomedical Engineering from California State University, Long Beach.
Fred Khosravi
Fred Khosravi is a Silicon Valley medical device entrepreneur with over 30 years of experience in medical technology, including management and executive positions in both large and small enterprises. He has co-founded Incept LLC and serves as its managing director, focusing on technology innovation and entrepreneurship in the life-sciences field and occasionally extending to information technology. Fred is credited as an inventor or co-inventor on over 200 patents and patent applications globally, holds degrees in mechanical engineering from Tennessee Tech University, and is involved in various organizations such as the Center for Strategic and International Studies, Spirit of America, and Technology for America.
